What are the top 10 leading biopharmaceutical stocks?
Pharmaceutical companies, as industry leaders, have strong research and development capabilities and a rich product line, providing patients with a full range of medical protection services. The stocks of these companies have performed well in the capital market and have significant long-term investment value. The following editorial brings what are the top ten leading stocks of biopharmaceuticals, which are of great benefit to all of you, let's take a look together.
Biopharmaceutical top ten leading stocks
Biopharmaceutical top ten leading stocks are: Hengrui Pharmaceutical (600276), Aier Eye (300015), Miles Medical (300760), Changchun High-tech (000661), WuXi Kande (603259), Tigermed (300347) Iwu Bio(300357), Tongce Medical(600763), Antu Bio(603658), Hualan Bio(002007).
Basic rules of stock trading:
1, stock T1 trading system:
The stocks bought on the day can not be sold on the same day, and can only be sold on the next trading day, and the funds for selling stocks on the same day can not be taken out on the same day, and can only be taken out on the second trading day.
2, stock trading hours
Non-statutory holidays from Monday to Friday, 9:30-11:30 a.m., 13:00-15:00 p.m. All holidays or weekends, A shares will be closed.
What are the leading stocks in the biomedical sector
The biomedical sector is one of the hot industries in the current capital market, and there are a number of listed companies with strong competitiveness and performance.
The stocks that are the leading ones mainly include: United Amino Acids, Hengrui Medicine, WuXi Biotechnology, Myriad Medical and so on. These companies in the field of biopharmaceuticals, medical diagnostics, health services and other areas of high technology content and innovation, market prospects, investors can pay attention to these companies with leading potential, according to the actual situation of prudent investment.
What are the leading stocks of traditional Chinese medicine stocks
The leading stocks of traditional Chinese medicine are Guangxin Pharmaceuticals (300519), Xinzi Pharmaceuticals (002118), Shenlong Rongfa (300534), Yunnan Baiyao (00538), Tongrentang (600085), Pientzehuang (600436).
Expanded information:
1. Other Chinese medicine concept stocks include:
1. Taiantang:In the past 7 trading days, Taiantang dropped 20.26%, with the highest price of 6.48 yuan and the total market capitalization down 851 million yuan, or 20.26%.
2. Yisheng Pharmaceuticals:Reviewing the past 7 trading days, Yisheng Pharmaceuticals fell 6 days in a row. The full session fell 9.38%, the highest price of 8.58 yuan, the lowest price of 9.14 yuan,*** traded 40,196,600 lots.
3. Ealing Pharmaceuticals:Ealing Pharmaceuticals shares are down 15.08% in the last 7 days, up 2.26% in 2022, with a high price of $25.76 and a market capitalization of $34.784 billion.
Pharmaceutical stocks leading stocks are which
Leading stock name leading stock code belongs to the plate industry category associated with the reason Fuxiang Pharmaceuticals 300497 GEM Pharmaceuticals and Biologicals β- the world's mainstream supplier of endocannabinoid enzyme inhibitors; the main production of special antimicrobial raw materials and their intermediates, including the series of sulbactam and tazobactam Series β-Three major series: lactamase inhibitor APIs and intermediates, and carbapenem antibacterial APIs and intermediates. Among them, tazobactam and sulforaphane sulfonate are APIs and the others are intermediates. 2019 revenue was 5. Main business 39.8 billion yuan.7%. Minova 603538 Shanghai Pharmaceuticals and Biologicals exports the most specialty APIs to Europe One of the domestic companies successfully developed and produced APIs and intermediates for sartan, resuvastatin, atorvastatin, clopidogrel, and esomeprazole; Liaoyuan Pharmaceuticals targeted products for cardiovascular, antidepressant, and psychoactive APIs and drug intermediates; and Krka, dd and Novomesto A joint venture was established with revenues of $974 million from intermediates and APIs in 2019, accounting for $8.2 billion.5% of the main business. Zixin Pharmaceuticals 002118 SME Pharmaceuticals and Biologicals National secondary protection of traditional Chinese medicine has for 3 kinds. Zixin Pharmaceutical 002118 small and medium-sized board of medicine and biology national secondary protection of traditional Chinese medicine has for three kinds. The products mainly include four wonderful pills, Huo bile tablets, kidney fukang capsule, blood circulation and vein tablet, split pill, Erding granules, children's white shellfish, and so on. , which are used to treat rheumatism, ear, nose and throat, urinary system, cardiovascular, cerebrovascular, liver and gallbladder, and digestive system diseases; the former includes white ginseng, red ginseng, dried ginseng, ginseng biloba beverage, ginseng fruit and vegetable fermented beverage, etc. Since 2019, ginseng product revenues have been US$384 million, accounting for US$4.4 billion.7% of the revenue from proprietary Chinese medicines products was 4%.6 billion, accounting for US$5.4 billion.1%.
What are the leading stocks of listed pharmaceutical companies
The leading stocks of listed pharmaceutical companies in 2023 are as follows:
1, ST Yikang (000150), up 5.45%.
2, ST Fu Ren (600781), up 4.72%.
3, Sincere Pharmaceuticals (603811), up 3.77%.
4, Chengdu Pilot (688222), up 3.62%.
5, Xing Qi ophthalmic (300573), up 2.69%.